Abstract
Osteoarthritis (OA) is a severe disease caused by wear and inflammation of joints. In this study, phospholipid-coated mesoporous silica nanoparticles (MSNs@lip) were prepared in order to treat OA at an early stage. The phospholipid layer has excellent lubrication capability in aqueous media due to the hydration lubrication mechanism, while mesoporous silica nanoparticles (MSNs) act as effective drug nanocarriers. The MSNs@lip were characterized by scanning electron microscope, transmission electron microscope, Fourier transform infrared spectrum, X-ray photoelectron spectrum, thermogravimetric analysis and dynamic light scattering techniques to confirm that the phospholipid layer was coated onto the surface of MSNs successfully. A series of tribological tests were performed under different experimental conditions, and the results showed that MSNs@lip with multi-layers of phospholipids greatly reduced the friction coefficient in comparison with MSNs. Additionally, MSNs@lip demonstrated sustained drug release behavior and were biocompatible based on CCK-8 assay using MC3T3-E1 cells. The MSNs@lip developed in the present study, acting as effective lubricating drug nanocarriers, may represent a promising strategy to treat early stage OA by lubrication enhancement and drug delivery therapy.
Highlights
Osteoarthritis (OA) is a common chronic joint disease suffered by millions of patients, which is featured by wear and degeneration of articular cartilage [1]
The phospholipid layers were coated onto the surface of Mesoporous silica nanoparticles (MSNs) to produce the phospholipidcoated MSNs, i.e., MSNs@lip, which were characterized using SEM, TEM, Fourier transform infrared spectrum (FTIR), XPS, Thermogravimetric analysis (TGA) and dynamic light scattering technique (DLS)
MSNs@lip-1 and MSNs@lip-2 show clearly the phospholipid layers, which do not result in the blockage of the mesopores in MSNs
Summary
Osteoarthritis (OA) is a common chronic joint disease suffered by millions of patients, which is featured by wear and degeneration of articular cartilage [1]. The clinical treatment for end stage OA is artificial joint replacement [3,4], but treating OA at an early stage through a non-surgical technique is considered to be more preferable for patients. It can be anticipated that generally it is difficult for the drugs to reach joints partly due to the insufficiency of blood vessels in the articular cartilage, which results in a considerably low absorption rate [7]. Mesoporous silica nanoparticles (MSNs) are reported as efficient drug nanocarriers, which can achieve targeted and controlled drug delivery due to their highly ordered mesoporous structure, large surface area and possibility for further modification [9,10,11,12,13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
